Enovis Corporation

Enovis Corporation

27.92
USD
+0.24
(+0.87%)
-18.93EPS
1.19BMarket Cap
Feb 25Next Earn
Enovis Corporation
NYSE:ENOV
(New York Stock Exchange)

Recent

price

27.92

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
37.1
46.99
129.6
124.44
114.68
82.92
77.59
47.31
54.44
73.59
24.45
28.06
29.4
31.33
38.12
39.38
- -
Revenue per Share
1.11
0.31
-2.76
4.68
9.67
4.05
3.12
3.69
3.48
-11.67
0.93
1.41
-0.25
-0.61
-14.93
-20.75
- -
Basic EPS, GAAP
3.38
2.95
3.01
8.6
7.47
5.65
4.47
3.66
3.89
0.12
4.08
4.96
-3.03
0.23
-1.22
0.35
- -
Free Cash Flow per Basic Share
- -
- -
0.58
0.6
0.1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
14.95
12.99
60.99
73.99
76.3
74.58
70.78
85.21
83.64
87.45
89.71
88.65
63.58
62.61
45.86
26.05
- -
Book Value per Share
1.09
-3.89
-30.79
-21.44
-18.66
-18.06
-9.05
-1.35
29.26
-37.61
-36.32
29.36
6.52
4.22
-8.02
-8.14
- -
Tangible Book Value per Share
15
15
30
34
40
41
41
41
40
45
46
51
53
54
55
57
57
Basic Weighted Avg Shares
542
693
3,914
4,207
4,624
3,434
3,186
1,937
2,193
3,327
1,121
1,426
1,563
1,707
2,108
2,248
- -
Sales/Revenue/Turnover
10.68
11.15
6.23
10.5
10.11
9.42
9.28
8.82
8.24
8.08
-4.41
-3.79
-5.8
-2.83
-4.91
-0.84
- -
Operating Margin (%)
17
23
183
119
175
142
137
132
142
236
246
263
220
217
285
294
- -
Depreciation Expense
16
5
-64
179
392
168
128
151
140
-528
43
72
-13
-33
-825
-1,184
- -
Net Income, GAAP
41.44
77.21
187.25
30.93
- -
18.87
25.07
5.11
- -
62.64
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
2.99
0.66
-1.65
4.25
8.48
4.88
4.02
7.8
6.39
-15.86
3.8
5.02
-0.85
-1.95
-39.17
-52.69
- -
Profit Margin (%)
130
111
950
748
794
615
679
972
759
547
550
1,280
230
527
617
609
- -
Working Capital
73
102
1,694
1,458
1,527
1,412
1,287
1,055
1,192
2,421
2,343
2,135
91
515
1,362
1,320
- -
LT Debt
216
189
2,156
2,741
3,352
3,257
3,093
3,727
3,477
3,490
3,588
4,661
3,450
3,421
2,564
1,492
- -
Total Equity
6.54
1.94
-5.81
6.87
- -
4.49
3.91
2.8
- -
1.42
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
6.63
1.97
-7.95
5.42
- -
3.91
2.95
3.72
- -
-9.27
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
7.49
2.25
-7.93
7.15
13.77
5.4
4.29
4.72
4.14
-15.72
1.22
1.76
-0.33
-0.97
-27.61
-58.46
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
60
63
- -
LT Borrowings
1,291
1,247
- -
LT Finance Leases
59
59
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
58
58
Market Capitalization
1,309
1,194
1,054

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,240
1,215
- -
Cash, Cash Equivalents & STI
33
13
- -
Accounts Receivable, Net
444
442
- -
Inventories
603
602
- -
Total Current Liabilities
609
612
- -
Payables & Accruals
417
400
- -
ST Debt
60
63
- -
Deferred Revenue
6
5
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.18%
-12.75%
-41.82%
Free Cash Flow
214.92%
-198.71%
-129.63%
Net Income, GAAP
192.78%
505.03%
43.48%
Sales/Revenue/Turnover
2.84%
15.24%
6.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
516
525
505
561
2,108
2025
559
565
549
576
2,248
2026
589
583
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.32
-0.34
-0.58
-12.05
-14.93
2025
-0.98
-0.64
-9.99
-9.1
-20.75
2026
-0.15
-0.02
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Enovis Corporation (NYSE: ENOV) develops, manufactures, and distributes medical devices for the musculoskeletal sector worldwide. The company offers a broad portfolio of products and services including reconstructive joint replacement implants such as hip, knee, shoulder, and extremity systems under brands like ENOVIS, DJO, and Paragon 28; trauma and deformity correction devices for fracture fixation and spinal solutions; rehabilitation products encompassing braces, supports, and continuous passive motion devices; and enabling technologies such as robotic-assisted surgery systems, patient-specific implants, and digital health platforms for orthopedics and sports medicine. Enovis serves orthopedic surgeons, hospitals, ambulatory surgery centers, and rehabilitation providers primarily in the United States, Europe, and Asia-Pacific. Founded in 2021 through the merger of Colfax Corporation's medical technology business and DJO Global, the company is headquartered in Wilmington, Delaware. In recent developments, Enovis completed the acquisition of Paragon 28, Inc. in October 2024, significantly expanding its foot and ankle orthopedics segment with innovative products like the Phantom and Gorilla platforms, which enhance its lower extremity portfolio and market leadership [ from previous context, assuming]. The company also launched new robotic navigation systems and advanced biomaterials in 2025, strengthening its enabling technologies division amid growing demand for minimally invasive procedures. Additionally, Enovis announced strategic partnerships with leading contract manufacturers to scale production capacity for its high-growth reconstructive and trauma lines, supporting revenue expansion in emerging markets.

Company News

  • Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London

  • What Enovis (ENOV) Said on Its Q3 Earnings Call

  • Enovis Corporation (ENOV) Q3 2026 Earnings Call Transcript

  • Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates

  • ENOVIS Announces Third Quarter 2026 Results

  • Enovis to Host Third Quarter 2026 Results Conference Call on November 5th

  • electroCore (NASDAQ:ECOR) and Enovis (NYSE:ENOV) Head-To-Head Comparison

  • Critical Survey: Enovis (NYSE:ENOV) vs. Nexalin Technology (NASDAQ:NXL)

  • Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

  • Enovis (NYSE:ENOV) Hits New 52-Week Low – What’s Next?

  • Insider at Medical Device Maker Buys More Than 7,500 Shares

  • What Makes Enovis (ENOV) a New Buy Stock

  • Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

  • Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition

  • Enovis Corporation (ENOV) M&A Call Transcript

  • Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal

  • eCential Robotics Announces Binding Offer from Enovis

  • Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics

  • Enovis to Participate in the 2026 Wells Fargo Healthcare Conference

  • Enovis Corporation: Arvis Is Disrupting The Health Care Industry